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Abstract
The technology available for cancer diagnosis and prognosis is not yet satisfactory at the molecular level, and requires
further improvements. Micro RNAs (miRNAs) have been recently reported as useful biomarkers in diseases including cancer.
We performed a miRNA expression profiling study using peripheral blood from breast cancer patients to detect and identify
characteristic patterns. A total of 100 breast cancer patients and 89 healthy patients were recruited for miRNA genotyping
and expression profiling. We found that hs-miR-196a2 in premenopausal patients, and hs-miR-499, hs-miR-146a and hs-miR-
196a2 in postmenopausal patients, may discriminate breast cancer patients from healthy individuals. In addition, we found
a significant association between two microRNA polymorphisms (hs-miR-196a2 and hs-miR-499) and breast cancer risk.
However, no significant association between the hs-miR-146a gene and breast cancer risk was found. In summary, the study
demonstrates that peripheral blood miRNAs and their expression and genotypic profiles can be developed as biomarkers
for early diagnosis and prognosis of breast cancer.
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Introduction
Breast cancer incidence shows geographical variation, even in
ethnically homogeneous areas. Over the past few years, Saudi
Arabia has witnessed an increase in the occurrence of breast
cancer in its population. The increase could be a result of exposure
to environmental carcinogens, different lifestyles and reproductive
patterns, or differences in dietary or cultural practices of Saudi
women. In Saudi Arabia, breast cancer constitutes 18% of all
cancers in Saudi women [1]. Although locally advanced breast
tumor is unusual in Western countries, it constitutes more than
40% of all non-metastatic breast cancer in Saudi Arabia. In the
Saudi population, 21% of all female cancer diagnoses are breast
cancer. Age-adjusted breast cancer incidence rates in Western
countries are about five times higher than rates in less developed
countries [1]. However, in the 2002 annual report of the Saudi
National Cancer Registry, 26.4% of all female breast cancers in
Saudi Arabia develop before the age of 40, as compared with only
6.5% in the USA. It has been reported that young age is an
independent risk factor for female breast cancer in the Saudi
population [2].
MicroRNAs (miRNAs) are short (,19–23 nucleotides), non-
coding RNA molecules that are recognized as endogenous
physiological regulators of gene expression. These small RNAs
are capable of controlling gene expression either by repressing
translation and transcription [3], or by activating transcription [4].
MiRNAs are also known to play important roles in many
physiological and pathological processes, including tumorigenesis
[5], proliferation [6], hematopoiesis [7], metabolism [8], immune
function [9], epigenetics, and neurological diseases [10,11]. They
were also found to be useful in identifying lymphoma causes [12]
and the progression of certain neurological diseases [13].
According to UCSC genome browser (http://genome.ucsc.
edu), several SNPs falling within miRNA hairpin regions are
reported and are likely to have an expected reduced biological
effect, because they do not change substantially the structure of the
miRNA. Since miRNAs function as oncogenes or tumor
suppressors [3–5] altered expressions of miRNAs may contribute
to prostatic malignant transformation. Therefore, we hypothesized
that SNPs in miRNAs may be associated with breast cancer risk.
We evaluated the association of three selected SNPs (rs11614913,
rs2910164, and rs3746444), which are located at the miRNA
hairpin regions of, hsa-mir196a2, hsa-mir146a, and hsamir499,
respectively with breast cancer risk in a case–control study. A
single nucleotide polymorphism (SNP) located in the miRNA
binding site of a miRNA target may disrupt miRNA-target inter-
action, resulting in the deregulation of target gene expression, as
shown in non-small cell lung cancer [14]. Alternatively, a SNP
within the miRNA precursor may alter miRNA processing and
ultimately change the mature miRNA level, as was recently shown
for miR-146a in papillary thyroid carcinoma [15]. Such effects by
SNP on miRNA levels and function may modify breast cancer risk
in general, and may explain the different risk level for Saudi
women.
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are stable and resistant to nuclease digestion. Therefore, exa-
mination of miRNA expression levels in blood is reproducible and
is indicative of the disease state [16]. We hypothesized that specific
miRNA signatures in blood samples can be used to identify
biomarkers for diagnosis, prognosis or even etiology of a disease.
In this study, we show that disease progression and the breast
cancer stages could be identified from miRNA profiles, when




The clinicopathologic records for each patient were published
previously [17] (Table 1). The average age of the randomly
selected group of 100 breast carcinoma cases with stage I (24%),
stage II (39%), stage III (33%), and stage IV (2%) and two patients
undetermined disease was about 51.5 years. Fifty-eight percent of
the patients were premenopausal cases, with an average age of
37.5 years. The average age of postmenopausal patients was 61.2
years.
Expression of hs-miR-196a2, hs-miR-499 and hs-miR-146a
in blood from breast cancer patients and healthy
patients
Numerous publications have reported aberrant miRNA expres-
sion in cancer. Figure 1 shows the relative quantification of
miRNAs hs-miR-196a2, hs-miR-499 and hs-miR-146a in the
blood of 89 healthy individuals and 92 patients with breast cancer
(RNA quality or quantity was insufficient for expression study in 8
out of the 100 samples, which will be the subject of future
investigation; thus the final analyses included 92 cases out of the
100). To determine the differences in the relative expression profiles,
we performed univariate analyses using the Mann Whitney-U test.
Quantitative reverse transcriptase-polymerase chain reaction assays
confirmed this finding. As shown in Figure 2, the median values of hs-
miR-196a2 for the pre- and post-menopausal subgroups were
i n c r e a s e d3 . 8 - f o l d( P=0.0001) and 2.6-fold (P=0.008) respectively,
in comparison to healthy individuals. In contrast, the values for hs-
miR-499 (4.1-fold, P=0.005) and hs-miR-146a (4.6-fold, P=0.001)
could only discriminate the disease state in postmenopausal patients,
but not in premenopausal patients, when compared with healthy
individuals.
MicroRNA genotyping
Tables 2 and 3 show the genotypic frequencies of the three
polymorphic miRNA genes from genomic DNA extracted from
breast cancer cases and in controls. Significant association was
found between the two polymorphisms hs-miR-196a2 (rs11614913)
and hs-miR-499 (rs3746444) and breast cancer risk. However, no
significant association between hs-miR-146a (rs2910164) and breast
cancer risk was found. For hs-miR-196a2, the heterozygous
genotype (CT) showed risk for disease (P=0.01; OR=1.70). In
addition, the variant allele carrier (CT+TT) also displayed a higher
breast cancer frequency (65%) than controls (54%), showing a risk
patternforbreastcancer(P=0.01;OR=1.66).Similarly,forthehs-
miR-499 polymorphism, we found that the heterozygous genotype
(CT) conferred a much higher risk for developing breast cancer
(P=0.001; OR=2.27). The variant allele carrier (CT+CC) also
showed a higher risk pattern for breast cancer, with breast cancer
cases (70%) and controls (55%) (P#0.001; OR=1.97). The allelic
frequencies did not show any associations for the three polymor-
phisms (Table 4). Furthermore, PCR products were randomly
selected from the real-time master plate and were subjected to
electrophoresis on 2% agarose gel to confirm the genotype of the
three microRNA genes under study.
Association of microRNA expression with microRNA gene
variants
To further investigate the functional relevance of miRNA
gene polymorphism, correlation analysis between genotypes and
miRNA expression was performed (Figure 3). We found that
among the 92 breast cancer patients, 25 were of the rs11614913
TT genotype (hs-miR-196a2), 44 of the CT genotype, and 23 of
the CC genotype. The DCt value for hs-miR-499 of the rs3746444
Table 1. Characteristics of breast cancer patients.




age 61.2years) I II III IV
No. of patients (N=100) 58 42 13 50 35 2
doi:10.1371/journal.pone.0030049.t001
Figure 1. Relative expression of microRNAs in breast cancer
cases and control subjects. Total RNA including small RNA was
isolated from blood samples from healthy subjects and breast cancer
patients using the Blood RNA Isolation Kit (Qiagen, Germany). cDNA
was subjected to Real Time PCR using microRNAs assays (Qiagen,
Germany). Data derived from quantitative real-time PCR and presented
in DCT of relative threshold cycles indicating fold changes over normal
subjects. Normalization was performed with the small nuclear RNU1A in
blood samples. Results are mean values of triplicate experiments. Bars
denote standard error (SEM). P-values of the statistical evaluations of
miRNA levels were determined by Mann and Whitney-U test.
doi:10.1371/journal.pone.0030049.g001
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and the CC genotype was 4.1660.3, whereas DCt values for
mature hs-mir-196a according to different rs11614913 genotypes
were 5.8360.77 (24), 4.5360.75 (42), and 3.8960.28 (26),
respectively. However, the DCt value for the hs-miR-146a miRNA
(rs2910164) TT genotype was 1.7460.07 (29); the CT genotype
was 1.7260.06 (35), and 0.5960.28 (26) for the CC genotype
(P=0.437).
Discussion
In this study, we examined whether the expression profile of
three miRNAs (hs-miR-196a2, hs-miR-499 and hs-miR-146a) in
blood were associated with the diagnosis and progression of breast
cancer, based on the regulation of relevant target genes. The
present study reveals that hs-miR-196a2 may discriminate breast
cancer patients from healthy individuals in premenopausal
patients, while hs-miR-499, hs-miR-146a and hs-miR-196a2
may be relevant in postmenopausal patients. Recent studies have
Figure 2. Relative expression of microRNAs in pre- and post-menopausal breast cancer patients. Total RNA including small RNA was
isolated from blood samples from healthy subjects and breast cancer patients using the Blood RNA Isolation Kit (Qiagen, Germany). cDNA was
subjected to Real Time PCR using microRNAs assays (Qiagen, Germany). Data derived from quantitative real-time PCR and presented in DCT of
relative threshold cycles indicating fold changes over normal subjects. Normalization was performed with the small nuclear RNU1A in blood samples.
Results are mean values of triplicate experiments. Bars denote standard error (SEM). P-values of the statistical evaluations of miRNA levels were
determined by Mann and Whitney-U test.
doi:10.1371/journal.pone.0030049.g002
Table 2. Patients showing microRNA genetic variants
categorized by tumor stage (n).
Tumor stage +/+ +/2 2/2
hs-miR-196a2
I3 9 1
II 14 22 14
III 7 13 7




II 4 28 11
III 15 12 7




II 14 21 15
III 8 7 11
IV 2 0 0
Undermined 8
doi:10.1371/journal.pone.0030049.t002
Table 3. Distribution of microRNA gene genetic variants and
Odds ratio with 95% CI in breast cancer patients and control
subjects.
Genetic variants Control Patients OR (95% CI) P value
hs-miR-499
Wild type [+/+]4 5 3 0 1
ref
Heterozygous [+/2] 40 62 2.22(1.40–3.52) 0.001
Homozygous [2/2] 15 8 0.79(0.35–1.69) 0.56
Recessive Model 55 70 1.92(1.23–3.0) 0.001
hs-miR-196a2
Wild type [+/+]4 6 3 5 1
ref
Heterozygous [+/2] 50 63 1.65 (1.05–2.55) 0.01
Homozygous [2/2] 4 2 0.45(0.07–1.86) 0.25
Recessive Model 54 65 1.61(1.03–2.44) 0.01
hs-miR-146a
Wild type [+/+]5 1 4 8 1
ref
Heterozygous [+/2] 46 50 1.06(0.68–1.63) 0.51
Homozygous [2/2] 3 2 0.77(0.18–2.89) 0.71
Recessive Model 49 52 1.11(0.72–1.70) 0.41
doi:10.1371/journal.pone.0030049.t003
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suppressor genes, or genes that contribute to the carcinogenesis
[18]. Yu et al. [19] performed a genome-wide analysis of SNPs
within the 39-UTR miRNA binding sites of various human genes,
and found that there was significantly different allele frequencies of
some miRNA-binding SNPs reported in human cancer expressed
sequence tag libraries and the National Center for Biotechnology
Information SNPs database [20], suggesting that certain SNPs
located within miRNA binding sites may be over-represented in
individuals with cancer.
To the best of our knowledge, this is the first study to provide
evidence that common SNPs in miRNAs might play an important
role in breast cancer prediction. Recently, a strong link between
miRNAs that are altered, either structurally or in the number
of mature miRNAs, and cancer has been demonstrated [21].
Mutations, polymorphisms, misexpression, or altered mature
miRNA processing are likely to be pleiotropic and may contribute
to cancer susceptibility and progression. Inherited mutations or
rare SNPs in the primary transcripts of has-mir-15a and has-mir-16-
1 have been linked to familial chronic lymphocytic leukemia and
familial breast cancer [22], which was further supported in chronic
lymphocytic leukemia [23]. It has also been shown that miRNA
expression patterns have relevance to the biological and clinical
behavior of human solid tumors [24–26]. For example, hsa-mir-
196a was highly expressed in pancreatic [25] and breast cancers
[26] compared with normal tissues, and the elevated expression
was associated with significantly reduced survival for pancreatic
cancer [25].
In addition, the present study showed that hs-miR-196a2
heterozygous genotypes and variant allele carriers were signifi-
cantly associated with 1.8- and 1.7-fold, respectively, higher risk
for developing breast cancer. Similarly, hs-miR-499 was observed
to be a 2.3-fold greater risk for patients carrying the heterozygous
genotype, while variant allele carriers also revealed 2.0-fold risk
pattern for breast cancer. On the other hand, hs-miR-146a was
not found to be associated with the disease. Hence, in this po-
pulation-based study of breast cancer in Saudi Arabia, it was
observed that the genetic polymorphism in the hs-miR-196a2
(rs11614913) and hs-miR-499 (rs3746444) genes are associated
with increased risk of developing breast cancer. On the contrary,
the hs-miR-146a (rs2910164) gene was found to be a non-
significant factor. To the best of our knowledge, this is the first
study of the Saudi population to correlate miRNA polymorphism
with breast cancer susceptibility. Though our study has certain
limitations in terms of the non-significant association of the alleles
with breast cancer risk with reference to disease development,
nevertheless it has several strengths too. The control subjects
followed the Hardy-Weinberg equilibrium, all of our cases were
histopathologically confirmed and proper guidelines for ensuring
the quality of our genotyping were used. The non-significant
association of the polymorphisms with clinical parameters could be
due to the small sample size, or perhaps these polymorphisms do
not have a role in tumor metastasis and progression.
Protein based biomarkers from whole blood, serum or plasma
have been widely used over the years for clinical diagnosis and
prognosis. MiRNA-induced gene expression has also been shown
to contribute extensively to disease phenotype [27]. The apparent
roles of miRNAs in diseases have led many researchers to probe
the molecular mechanisms underlying pathogenesis and to develop
novel diagnostic and therapeutic agents [28]. We observed that
the miRNAs were stably expressed in circulation even several
months after the onset of breast cancer. This correlated with the
observation from Chen et al. [16] that miRNAs from serum are
stable, resistant to nuclease digestion and almost consistent among
individuals.
In conclusion, the results imply that individual and combined
genotypes of microRNA processing pathway genes may influence
breast cancer susceptibility. As a result, breast cancer-related
miRNAs may represent novel biomarkers, as they are potentially
useful in the diagnosis and prognosis, and the monitoring of
treatment response. When these important miRNAs are identified
and their functions elucidated, we can manipulate them for thera-
peutic benefit in a rational manner. The study provides the first
epidemiologic evidence evaluating the effects of genetic polymor-
phisms in pre-microRNA genes with breast cancer risk. These
findings propose that breast cancer-related miRNAs may eventu-
ally be exploited as therapeutic targets. Large cohort and diverse
ethnicity studies will be required to validate our results. This would
assist in a deeper understanding of the basic functions and
pathological alterations in microRNA needed to pave the way for
Table 4. Distribution of microRNA gene allelic variants and
Odds ratio with 95% CI in breast cancer patients and control
subjects.
Allelic variants Control Patients OR (95% CI) P value
hs-miR-499
T 130 122 1
ref
C 70 78 1.14(0.84–1.56) 0.18
hs-miR-196a2
C 142 133 1
ref
T 58 67 1.18(0.85–1.62) 0.18
hs-miR-146a
C 148 146 1
ref
G 52 54 1.01(0.71–1.40) 0.7
doi:10.1371/journal.pone.0030049.t004
Figure 3. Relative expression of microRNAs with respect to
genotype pattern. miRNAs were determined using SYBR Green
MicroRNA Assays adopting Quantitative Real Time PCR. Normalization
was performed with the small nuclear RNU1A in blood samples. Total
RNA including small RNA was isolated from blood samples from healthy
subjects and breast cancer patients using the Blood RNA Isolation Kit
(Qiagen, Germany). cDNA was subjected to Real Time PCR using
microRNAs assays (Qiagen, Germany). Data derived from quantitative
real-time PCR and presented in DCT of relative threshold cycles
indicating fold changes over normal subjects.Results are mean values of
triplicate experiments. Bars denote standard error (SEM). P-values of the
statistical evaluations of miRNA levels were determined by Mann and
Whitney-U test.
doi:10.1371/journal.pone.0030049.g003
MicroRNA and Breast Cancer
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variations in miRNA-regulated genes are important screening
tools for identifying individuals at high risk for developing breast
cancer, particularly at an early age. However, larger studies with
multi-ethnic groups are warranted to validate our findings.
Materials and Methods
Clinical methodology
A total of 100 breast cancer patients admitted to the King
Khalid University Hospital were selected for the study. The study
protocol included a standard oncological evaluation with subse-
quent review and outpatient follow-ups. In our study, we used
blood samples collected from breast cancer patients and healthy
volunteers. Demographic data, medical history and conventional
vascular risk factors were recorded in a standardized computerized
database and extracted from the medical records. The study
was approved by the hospital ethical committee board. Written
informed consent was obtained from all patients and control
subjects included in this study.
DNA extraction
GenomicDNA was extracted using the QIAamp DNAblood mini
kit (Qiagen, Hilden, Germany), as per manufacturer’s instructions.
MicroRNA extraction
Total RNA, including microRNA, was extracted from blood
samples using the Blood RNA isolation kit (Qiagen, Hilden,
Germany) as per manufacturer’s instructions. RNA concentration
was quantified using NanoDrop ND-1000 Spectrophotometer
(Thermo Fisher Scientific, USA). RNA quality was determined
using a 2% agarose gel.
Genotyping
SNP analysis was performed using a real-time PCR (RT-PCR)
allelic discrimination TaqMan assay (Applied Biosystems, Foster
City) with slight modifications. The assay included proprietary
non-labeled forward and reverse primers along with two pro-
prietary fluorescent TaqMan oligonucleotide probes (allele 1-
specific probe labeled with VIC fluorophore, allele 2-specific
probe labeled with FAM (6-carboxy- fluorescein fluorophore). All
PCRs were performed in duplicate. The reaction contained 50 ng
(10 mL) DNA, 9 mL TaqMan genotype PCR Master Mix (26),
and 1 mL allelic discrimination mix. RT-PCR was performed
using ABI Prism 7500 Fast Sequence Detection System (SDS;
Applied Biosystems, Foster City, California, USA) using the
following conditions: 50uC for 2 min, 95uC for 10 min, and then
40 cycles of amplification (92uC denaturation for 15 s, 62uC
annealing/extension for 60 s). The annealing temperature was
empirically determined (data not shown) to promote high probe
specificity without losing assay sensitivity. For each cycle, the SDS
software determined the DRn, which is the normalized (i.e.,
compared with a passive reference fluorophore) fluorescent signal
from the VIC- or FAM-labeled probe. For our analysis, we used
the DRn value after the final cycle because it proved more reliable
than the cycle at which the threshold was crossed.
cDNA synthesis and microRNA real-time PCR
MiRNA quantitation was determined using SYBR Green PCR.
Briefly, 100 ng of template RNA was reverse transcribed in 20 mL
using a universal stem-loop primer to generate the RT-product.
For the PCR reaction, 20 ng of RT-product was used. PCR was
performed using the Applied Biosystems 7500 Fast Sequence
Detection System. PCR reactions were performed in triplicate, in
three separate experiments. miRNAs were considered present
when the Ct values (threshold cycle) were lower than 35. RNU1A
was used as the normalization gene.
Statistical analysis
Statistical analyses were performed using the SPSS software
package, version 18.0 (SPSS Inc. Chicago, IL, USA). The chi-
square or the two-tailed Fischer’s exact test was used to identify
potential associations of miRNA concentrations in blood with
clinical and histopathological risk factors in breast cancer patients.
The cycle threshold (Ct) value for the genes was determined using
SDS software v1.2 (Applied Biosystems, Foster City, California,
USA). MiRNA expression level was normalized to the internal
control RNU1A. The relative gene expression was calculated
as 2
2A ¨Ct. The miRNA expression change observed in patients
in relation to control group was determined using the 2
2A ¨A ¨Ct
method. Statistical significance was determined using the Student’s
t-test and was considered significant if P,0.05.
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